Key result
Diabetic status is not linked to increased mortality versus normal glucose post-ACS.
Why the study?
Does glucometabolic status affect short-term prognosis in patients after acute coronary syndrome undergoing cardiac rehabilitation?
Cohort (n=1,614)
Yes
Does glucometabolic status affect short-term prognosis in patients after acute coronary syndrome undergoing cardiac rehabilitation?
Absolute Event Rate: 1.2% vs 1.5%
p-value: p=NS
In patients undergoing cardiac rehabilitation after a first acute coronary syndrome, short-term prognosis is determined by end-organ damage rather than glucometabolic status, though diabetic patients achieve lipid targets to a lesser extent.
Short-term post-ACS prognosis in rehabilitation may hinge on end-organ damage rather than diabetes; leaves open targeted lipid optimization trials in diabetics.
BACKGROUND: Patients with pathological glucometabolism are at increased risk of recurrent cardiovascular events after acute coronary syndrome (ACS). The goal of this study was to investigate the association of glucometabolism and the one-year outcome of cardiac rehabilitation patients. DESIGN: Prospective multicentre registry from four German rehabilitation clinics. METHODS: During 2005-2006, 1614 consecutive patients (85.9% male, mean age 55 ± 10.3 years) were included after the first ACS (mean 18.9 days) and classified into group 1 (apparent diabetes mellitus, n = 268), group 2 (no diabetes, impaired oral glucose tolerance [OGT], n = 185), and group 3 (normal fasting glucose and normal OGT, n = 1161). The mean follow-up was 13.4 months and the follow-up events were analysed by multivariate logistic regression models with backward elimination. RESULTS: The overall mortality was 1.3% (group 1: 1.2%; group 2: 1.8%; group 3: 1.5%; p(Trend) = NS). The target blood pressure values at discharge (<140/90 mmHg) were achieved by 88.7%, 89.1% and 90.8% of patients in groups 1, 2 and 3, respectively (p(Trend) = NS). The target value for LDL cholesterol (<100 mg/dl) was attained by 87.0%, 80.8% and 81.5% of the patients in groups 1, 2 and 3, respectively (p(Trend) = NS). There was a trend of a lower proportion of patients reaching the target values for HDL-C of 46.1%, 51.4% and 60.8% (p(Trend) < 0.001) and triglycerides of 65.1%, 79.9% and 74.6% (p(Trend) = 0.004) for groups 1, 2 and 3, respectively. The strongest multivariate predictors for overall mortality were patients experiencing a previous stroke (OR, 6.29 [95% CI: 1.06-37.19]; p = 0.042) and, with a trend, peripheral arterial disease (OR, 3.60 [95% CI: 0.95-13.68]; p = 0.061). In the multivariate analysis, the diabetic state had no association with poor outcomes (i.e. death or rehospitalization). CONCLUSION: The short-term prognosis for both diabetic and non-diabetic patients was good and was determined by end organ damage rather than by glucometabolic status. Diabetic patients received comparable (and not more aggressive) pharmacotherapy and therefore achieved target values for cardiovascular risk factors to a lesser extent than the non-diabetic and pre-diabetic patients.
No takes yet. Share an insight, caveat, or question.
Reibis et al. (2011) conducted a cohort in Acute coronary syndrome (n=1,614). Apparent diabetes mellitus vs. Normal fasting glucose and normal oral glucose tolerance was evaluated on Overall mortality (p=NS). Diabetic status was not associated with increased overall mortality (1.2% for diabetes vs 1.5% for normal glucose, p=NS) in patients after acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: